Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIMO Trial of protease inhibitor monotherapy maintenance in suppressed HIV infection
2009-016697-32Phase 3Completed
- Sponsor
- National Institute for Infectious Diseases Lazzaro Spallanzani
- Start
- Nov 2009
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir, ritonavir and darunavir in human immunodeficiency virus infection (HIV) (3 arms), sponsored by National Institute for Infectious Diseases Lazzaro Spallanzani. Primary endpoint: Virologic suppression at week 48. Started Nov 2009; status: completed.
02
Drugs
lopinavirritonavirdarunavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-016697-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016697-32.